Edwards Lifesciences Corporation $EW Shares Bought by iSAM Funds UK Ltd

iSAM Funds UK Ltd lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 120.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,100 shares of the medical research company’s stock after purchasing an additional 6,623 shares during the quarter. Edwards Lifesciences accounts for approximately 0.8% of iSAM Funds UK Ltd’s holdings, making the stock its 28th largest position. iSAM Funds UK Ltd’s holdings in Edwards Lifesciences were worth $1,095,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Rehmann Capital Advisory Group lifted its holdings in Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares during the period. McIlrath & Eck LLC raised its position in shares of Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after buying an additional 135 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after acquiring an additional 136 shares during the period. Stephens Inc. AR lifted its stake in shares of Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock worth $239,000 after acquiring an additional 144 shares during the period. Finally, Aspen Investment Management Inc boosted its holdings in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company’s stock valued at $885,000 after acquiring an additional 150 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.27.

Insider Activity

In other news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 5,045 shares of company stock worth $457,749. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $90.80 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm’s 50 day moving average is $89.74 and its 200-day moving average is $85.36. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The stock has a market capitalization of $52.28 billion, a P/E ratio of 52.18, a P/E/G ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.